340 related articles for article (PubMed ID: 36834548)
1. Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing.
Bernal L; Pinzi L; Rastelli G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834548
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
Bahmad HF; Demus T; Moubarak MM; Daher D; Alvarez Moreno JC; Polit F; Lopez O; Merhe A; Abou-Kheir W; Nieder AM; Poppiti R; Omarzai Y
Med Sci (Basel); 2022 Feb; 10(1):. PubMed ID: 35225948
[TBL] [Abstract][Full Text] [Related]
3. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential biological targets of oxindole scaffolds via
Tinivella A; Pinzi L; Gambacorta G; Baxendale I; Rastelli G
F1000Res; 2022; 11():. PubMed ID: 37767081
[No Abstract] [Full Text] [Related]
5. Integrating transcriptomics and network analysis-based multiplexed drug repurposing to screen drug candidates for M2 macrophage-associated castration-resistant prostate cancer bone metastases.
Chang J; Jiang Z; Ma T; Li J; Chen J; Ye P; Feng L
Front Immunol; 2022; 13():989972. PubMed ID: 36389722
[TBL] [Abstract][Full Text] [Related]
6. Drug repositioning for prostate cancer: using a data-driven approach to gain new insights.
Wang Q; Xu R
AMIA Annu Symp Proc; 2017; 2017():1724-1733. PubMed ID: 29854243
[TBL] [Abstract][Full Text] [Related]
7. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
9. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
10. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Efficacy of Repurposing Drugs in the Treatment of Prostate Cancer.
Lourenço T; Vale N
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835564
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
13. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer.
Abern MR; Terris MK; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
Cancer; 2014 Jun; 120(11):1656-62. PubMed ID: 24647966
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
Conteduca V; Aieta M; Amadori D; De Giorgi U
Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
[TBL] [Abstract][Full Text] [Related]
15. Androgen Deprivation Therapy for Prostate Cancer.
Pagliarulo V
Adv Exp Med Biol; 2018; 1096():1-30. PubMed ID: 30324345
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.
Johnson RP; Ratnacaram CK; Kumar L; Jose J
Drug Resist Updat; 2022 Sep; 64():100865. PubMed ID: 36099796
[TBL] [Abstract][Full Text] [Related]
17. Current perspectives in the treatment of advanced prostate cancer.
Valdespino V; Tsagozis P; Pisa P
Med Oncol; 2007; 24(3):273-86. PubMed ID: 17873302
[TBL] [Abstract][Full Text] [Related]
18. [Third generation anti-androgen therapy of advanced prostate cancer].
Ohlmann CH; Kamradt J; Stöckle M
Urologe A; 2012 Apr; 51(4):522-6. PubMed ID: 22113551
[TBL] [Abstract][Full Text] [Related]
19. Drug Repositioning of the α
Florent R; Poulain L; N'Diaye M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727149
[TBL] [Abstract][Full Text] [Related]
20. The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.
Chellini L; Pieraccioli M; Sette C; Paronetto MP
J Exp Clin Cancer Res; 2022 May; 41(1):178. PubMed ID: 35590370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
